#BEGIN_DRUGCARD DB07776

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
42491

# Chemical_Formula:
C15H10O2

# Chemical_IUPAC_Name:
2-phenyl-4H-chromen-4-one

# Chemical_Structure:
Not Available

# Creation_Date:
2010-09-15 15:25:42 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
2-PHENYL-4H-CHROMEN-4-ONE

# HET_ID:
FLN

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C15H10O2/c16-13-10-15(11-6-2-1-3-7-11)17-14-9-5-4-8-12(13)14/h1-10H

# InChI_Key:
InChIKey=VHBFFQKBGNRLFZ-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
7782

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
222.2387

# Molecular_Weight_Mono:
222.068079564

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
3.54

# Predicted_LogS:
-4.4

# Predicted_Water_Solubility:
8.19e-03 g/l

# Primary_Accession_No:
DB07776

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
10680

# PubChem_Substance_ID:
99444247

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
O=C1C=C(OC2=CC=CC=C12)C1=CC=CC=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:26:02 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_1_Essentiality:
Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
D10996

# Drug_Target_1_GenBank_ID_Protein:
398596

# Drug_Target_1_GeneCard_ID:
ncsA

# Drug_Target_1_Gene_Name:
ncsA

# Drug_Target_1_Gene_Sequence:
>444 bp
GTGGTCCCCATTTCCATCATCAGGAATCGAGTAGCGAAGGTCGCCGTCGGCTCGGCGGCG
GTGCTGGGGCTCGCCGTAGGGTTCCAGACCCCGGCCGTGGCCGCGGCGCCGACGGCTACG
GTGACTCCGTCGTCCGGTCTGTCCGACGGCACCGTGGTCAAGGTCGCCGGCGCGGGTCTC
CAGGCCGGAACGGCCTACGACGTCGGGCAGTGCGCGTGGGTGGACACCGGTGTTCTCGCG
TGCAACCCGGCGGACTTCTCCTCCGTGACCGCGGACGCCAACGGCTCCGCGAGCACGTCG
CTGACGGTGCGCCGCTCCTTCGAGGGCTTCCTCTTCGACGGCACCCGCTGGGGCACCGTG
GACTGCACCACCGCGGCCTGCCAGGTCGGCCTCTCGGACGCTGCGGGCAACGGCCCGGAG
GGTGTGGCGATCTCCTTCAACTGA

# Drug_Target_1_General_Function:
Involved in DNA binding

# Drug_Target_1_General_References:
1531194	Adjadj E, Quiniou E, Mispelter J, Favaudon V, Lhoste JM: Three-dimensional solution structure of apo-neocarzinostatin from Streptomyces carzinostaticus determined by NMR spectroscopy. Eur J Biochem. 1992 Feb 1;203(3):505-11.
1533878	Gao X: Three-dimensional solution structure of apo-neocarzinostatin. J Mol Biol. 1992 May 5;225(1):125-35.
1831044	Gao XL, Burkhart W: Two- and three-dimensional proton NMR studies of apo-neocarzinostatin. Biochemistry. 1991 Aug 6;30(31):7730-9.
2142075	Adjadj E, Mispelter J, Quiniou E, Dimicoli JL, Favaudon V, Lhoste JM: Proton NMR studies of apo-neocarzinostatin from Streptomyces carzinostaticus. Sequence-specific assignment and secondary structure. Eur J Biochem. 1990 Jun 20;190(2):263-71.
2147566	Remerowski ML, Glaser SJ, Sieker LC, Samy TS, Drobny GP: Sequential 1H NMR assignments and secondary structure of aponeocarzinostatin in solution. Biochemistry. 1990 Sep 11;29(36):8401-9.
2938543	Kuromizu K, Tsunasawa S, Maeda H, Abe O, Sakiyama F: Reexamination of the primary structure of an antitumor protein, neocarzinostatin. Arch Biochem Biophys. 1986 Apr;246(1):199-205.
6236220	Gibson BW, Herlihy WC, Samy TS, Hahm KS, Maeda H, Meienhofer J, Biemann K: A revised primary structure for neocarzinostatin based on fast atom bombardment and gas chromatographic-mass spectrometry. J Biol Chem. 1984 Sep 10;259(17):10801-6.
8235619	Kim KH, Kwon BM, Myers AG, Rees DC: Crystal structure of neocarzinostatin, an antitumor protein-chromophore complex. Science. 1993 Nov 12;262(5136):1042-6.
8369747	Sakata N, Minamitani S, Kanbe T, Hori M, Hamada M, Edo K: The amino acid sequence of neocarzinostatin apoprotein deduced from the base sequence of the gene. Biol Pharm Bull. 1993 Jan;16(1):26-8.
8477746	Teplyakov A, Obmolova G, Wilson K, Kuromizu K: Crystal structure of apo-neocarzinostatin at 0.15-nm resolution. Eur J Biochem. 1993 Apr 15;213(2):737-41.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6583

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
14455.1

# Drug_Target_1_Name:
Neocarzinostatin

# Drug_Target_1_Number_of_Residues:
147

# Drug_Target_1_PDB_ID:
1O5P

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00960	Neocarzinostat

# Drug_Target_1_Protein_Sequence:
>Neocarzinostatin
MVPISIIRNRVAKVAVGSAAVLGLAVGFQTPAVAAAPTATVTPSSGLSDGTVVKVAGAGL
QAGTAYDVGQCAWVDTGVLACNPADFSSVTADANGSASTSLTVRRSFEGFLFDGTRWGTV
DCTTAACQVGLSDAAGNGPEGVAISFN

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-34

# Drug_Target_1_Specific_Function:
NCS has antibiotic activity (for Gram-positive bacteria) and antitumor activity (for certain mouse tumors). NCS binds non- covalently to a chromophore which is the cytotoxic and mutagenic component of the antibiotic. The chromophore binds to DNA as a weak intercalator and causes single- and double-strand breaks

# Drug_Target_1_SwissProt_ID:
P0A3R9

# Drug_Target_1_SwissProt_Name:
NCZS_STRCZ

# Drug_Target_1_Synonyms:
MMC
Mitomalcin
NCS

# Drug_Target_1_Theoretical_pI:
4.34

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB07776
